James Burton
Concepts (403)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 33 | 2025 | 871 | 3.620 |
Why?
| | Hepatitis C | 17 | 2021 | 271 | 2.470 |
Why?
| | Antiviral Agents | 17 | 2021 | 744 | 2.080 |
Why?
| | Hepatitis C, Chronic | 11 | 2021 | 164 | 2.060 |
Why?
| | Ribavirin | 8 | 2015 | 91 | 1.420 |
Why?
| | Hepacivirus | 11 | 2021 | 261 | 0.860 |
Why?
| | Protease Inhibitors | 3 | 2018 | 107 | 0.850 |
Why?
| | Proline | 6 | 2015 | 79 | 0.840 |
Why?
| | Liver Function Tests | 3 | 2022 | 114 | 0.750 |
Why?
| | Kidney Transplantation | 4 | 2023 | 708 | 0.750 |
Why?
| | Liver | 11 | 2023 | 1943 | 0.700 |
Why?
| | Oligopeptides | 5 | 2015 | 271 | 0.680 |
Why?
| | Interferon-alpha | 3 | 2014 | 198 | 0.680 |
Why?
| | Drug Therapy, Combination | 12 | 2018 | 1066 | 0.640 |
Why?
| | Liver Failure | 4 | 2016 | 94 | 0.630 |
Why?
| | Patient Selection | 3 | 2020 | 696 | 0.600 |
Why?
| | Polyethylene Glycols | 4 | 2014 | 641 | 0.580 |
Why?
| | Interferons | 4 | 2015 | 202 | 0.560 |
Why?
| | Living Donors | 7 | 2022 | 295 | 0.530 |
Why?
| | Graft Rejection | 4 | 2018 | 624 | 0.520 |
Why?
| | Recurrence | 12 | 2015 | 1060 | 0.470 |
Why?
| | Postoperative Complications | 5 | 2022 | 2654 | 0.420 |
Why?
| | Non-alcoholic Fatty Liver Disease | 3 | 2022 | 279 | 0.380 |
Why?
| | Colonoscopy | 2 | 2024 | 245 | 0.350 |
Why?
| | Immunocompromised Host | 1 | 2013 | 202 | 0.350 |
Why?
| | Viral Nonstructural Proteins | 2 | 2014 | 65 | 0.330 |
Why?
| | Humans | 78 | 2025 | 137585 | 0.320 |
Why?
| | Graft Survival | 4 | 2023 | 535 | 0.310 |
Why?
| | Home Care Services, Hospital-Based | 2 | 1999 | 10 | 0.300 |
Why?
| | Middle Aged | 37 | 2024 | 33479 | 0.300 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2008 | 385 | 0.290 |
Why?
| | Tissue Donors | 4 | 2021 | 425 | 0.290 |
Why?
| | Decision Support Techniques | 2 | 2018 | 421 | 0.270 |
Why?
| | Simeprevir | 2 | 2018 | 9 | 0.270 |
Why?
| | Esophageal and Gastric Varices | 1 | 2007 | 40 | 0.270 |
Why?
| | Acute Disease | 7 | 2008 | 1007 | 0.260 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2828 | 0.250 |
Why?
| | Health Services for the Aged | 5 | 2000 | 80 | 0.240 |
Why?
| | Tissue and Organ Procurement | 2 | 2023 | 321 | 0.240 |
Why?
| | Liver Cirrhosis | 3 | 2015 | 316 | 0.230 |
Why?
| | Reproducibility of Results | 5 | 2022 | 3284 | 0.230 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2008 | 1091 | 0.230 |
Why?
| | Cholates | 2 | 2022 | 2 | 0.230 |
Why?
| | Geriatrics | 7 | 2000 | 98 | 0.220 |
Why?
| | Health Care Rationing | 1 | 2004 | 59 | 0.220 |
Why?
| | Solitary Kidney | 1 | 2023 | 5 | 0.210 |
Why?
| | Male | 42 | 2024 | 67762 | 0.210 |
Why?
| | Home Care Services | 3 | 1997 | 257 | 0.210 |
Why?
| | Viremia | 3 | 2021 | 138 | 0.210 |
Why?
| | United States | 17 | 2023 | 14841 | 0.210 |
Why?
| | Cecal Neoplasms | 1 | 2003 | 1 | 0.210 |
Why?
| | Jejunoileal Bypass | 1 | 2003 | 1 | 0.210 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2024 | 89 | 0.210 |
Why?
| | Aged | 30 | 2024 | 23961 | 0.210 |
Why?
| | Sensitivity and Specificity | 2 | 2024 | 1946 | 0.200 |
Why?
| | Liver Diseases | 1 | 2006 | 315 | 0.200 |
Why?
| | Reoperation | 4 | 2007 | 573 | 0.200 |
Why?
| | Colonic Polyps | 1 | 2024 | 88 | 0.200 |
Why?
| | Mushroom Poisoning | 1 | 2002 | 7 | 0.200 |
Why?
| | HIV Seropositivity | 1 | 2023 | 125 | 0.200 |
Why?
| | Female | 41 | 2024 | 73304 | 0.200 |
Why?
| | Treatment Outcome | 15 | 2022 | 10811 | 0.200 |
Why?
| | Cholangitis | 1 | 2022 | 21 | 0.190 |
Why?
| | Transplant Recipients | 2 | 2021 | 184 | 0.180 |
Why?
| | Forecasting | 3 | 2014 | 389 | 0.180 |
Why?
| | Recombinant Proteins | 4 | 2014 | 1353 | 0.180 |
Why?
| | Liver Circulation | 1 | 2021 | 20 | 0.180 |
Why?
| | Cholangitis, Sclerosing | 1 | 2022 | 75 | 0.170 |
Why?
| | Artificial Intelligence | 1 | 2024 | 279 | 0.170 |
Why?
| | Famous Persons | 1 | 2000 | 7 | 0.170 |
Why?
| | Deuterium | 1 | 2021 | 99 | 0.170 |
Why?
| | Adult | 22 | 2024 | 37929 | 0.170 |
Why?
| | Nursing Homes | 2 | 1994 | 181 | 0.170 |
Why?
| | Carbon Isotopes | 1 | 2021 | 144 | 0.170 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2020 | 31 | 0.170 |
Why?
| | Colorectal Neoplasms | 2 | 2025 | 806 | 0.160 |
Why?
| | Healthy Volunteers | 1 | 2021 | 199 | 0.160 |
Why?
| | Blood Coagulation Disorders | 1 | 2022 | 173 | 0.160 |
Why?
| | Sofosbuvir | 2 | 2021 | 62 | 0.160 |
Why?
| | HIV-1 | 2 | 2023 | 864 | 0.160 |
Why?
| | Donor Selection | 1 | 2020 | 77 | 0.160 |
Why?
| | Allografts | 1 | 2020 | 146 | 0.160 |
Why?
| | Reference Values | 1 | 2021 | 816 | 0.150 |
Why?
| | Carbamates | 2 | 2021 | 50 | 0.150 |
Why?
| | Antibiotic Prophylaxis | 1 | 2020 | 119 | 0.150 |
Why?
| | Kidney | 3 | 2023 | 1468 | 0.150 |
Why?
| | Genotype | 4 | 2023 | 1916 | 0.150 |
Why?
| | Hepatitis, Autoimmune | 1 | 2018 | 20 | 0.150 |
Why?
| | Geological Phenomena | 1 | 2018 | 2 | 0.150 |
Why?
| | Liver Neoplasms | 1 | 2025 | 786 | 0.150 |
Why?
| | Coronary Artery Disease | 2 | 2020 | 698 | 0.140 |
Why?
| | Biopsy | 2 | 2020 | 1129 | 0.140 |
Why?
| | Buffaloes | 1 | 2018 | 13 | 0.140 |
Why?
| | Practice Patterns, Physicians' | 2 | 2005 | 1313 | 0.140 |
Why?
| | Coronary Angiography | 3 | 2020 | 317 | 0.140 |
Why?
| | Cohort Studies | 6 | 2018 | 5742 | 0.140 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2018 | 32 | 0.140 |
Why?
| | Physician-Patient Relations | 3 | 2000 | 548 | 0.140 |
Why?
| | Geriatric Assessment | 2 | 1997 | 224 | 0.140 |
Why?
| | Eligibility Determination | 2 | 1997 | 65 | 0.140 |
Why?
| | RNA, Viral | 4 | 2015 | 656 | 0.140 |
Why?
| | Prospective Studies | 8 | 2024 | 7604 | 0.140 |
Why?
| | Leukocyte Count | 1 | 2018 | 329 | 0.140 |
Why?
| | Thrombolytic Therapy | 2 | 1997 | 142 | 0.140 |
Why?
| | Drug Interactions | 3 | 2013 | 410 | 0.130 |
Why?
| | Forkhead Transcription Factors | 2 | 2008 | 191 | 0.130 |
Why?
| | Genetic Speciation | 1 | 2018 | 81 | 0.130 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 110 | 0.130 |
Why?
| | HIV Integrase Inhibitors | 1 | 2018 | 70 | 0.130 |
Why?
| | Family Planning Policy | 1 | 2016 | 1 | 0.130 |
Why?
| | End Stage Liver Disease | 1 | 2018 | 82 | 0.130 |
Why?
| | Consensus | 1 | 2020 | 683 | 0.130 |
Why?
| | Anti-HIV Agents | 1 | 2023 | 778 | 0.130 |
Why?
| | Odds Ratio | 4 | 2015 | 1070 | 0.130 |
Why?
| | Health Planning | 1 | 2016 | 47 | 0.120 |
Why?
| | Adenocarcinoma | 1 | 2003 | 940 | 0.120 |
Why?
| | Retrospective Studies | 11 | 2022 | 15657 | 0.120 |
Why?
| | Public Policy | 1 | 2016 | 85 | 0.120 |
Why?
| | Drug Resistance, Viral | 2 | 2023 | 116 | 0.120 |
Why?
| | Long-Term Care | 1 | 2016 | 107 | 0.120 |
Why?
| | Aortic Valve Insufficiency | 1 | 2015 | 47 | 0.120 |
Why?
| | Population Dynamics | 1 | 2016 | 151 | 0.120 |
Why?
| | Swine | 1 | 2018 | 775 | 0.120 |
Why?
| | Fibrosis | 1 | 2018 | 552 | 0.120 |
Why?
| | Prognosis | 5 | 2020 | 4030 | 0.120 |
Why?
| | Macrocyclic Compounds | 1 | 2014 | 9 | 0.120 |
Why?
| | Program Evaluation | 1 | 1999 | 898 | 0.110 |
Why?
| | Time Factors | 10 | 2018 | 6828 | 0.110 |
Why?
| | Survival Analysis | 4 | 2018 | 1325 | 0.110 |
Why?
| | Anilides | 1 | 2014 | 73 | 0.110 |
Why?
| | Comprehensive Health Care | 1 | 1994 | 24 | 0.110 |
Why?
| | Homes for the Aged | 1 | 1994 | 34 | 0.110 |
Why?
| | Developing Countries | 1 | 2016 | 307 | 0.110 |
Why?
| | Glucocorticoids | 1 | 2018 | 594 | 0.110 |
Why?
| | Patient Satisfaction | 1 | 1998 | 660 | 0.110 |
Why?
| | Young Adult | 7 | 2021 | 13209 | 0.110 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2015 | 130 | 0.110 |
Why?
| | Factor Xa Inhibitors | 2 | 2005 | 172 | 0.100 |
Why?
| | Transplantation | 1 | 2013 | 34 | 0.100 |
Why?
| | Serine Proteinase Inhibitors | 1 | 2013 | 47 | 0.100 |
Why?
| | Aortic Valve Stenosis | 1 | 2015 | 229 | 0.100 |
Why?
| | Spinal Diseases | 1 | 1993 | 48 | 0.100 |
Why?
| | Multivariate Analysis | 3 | 2015 | 1509 | 0.100 |
Why?
| | Pyridazines | 1 | 2013 | 56 | 0.100 |
Why?
| | Follow-Up Studies | 6 | 2016 | 5131 | 0.100 |
Why?
| | Myocardial Infarction | 3 | 2005 | 1046 | 0.100 |
Why?
| | DEAD-box RNA Helicases | 1 | 2013 | 76 | 0.090 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2012 | 78 | 0.090 |
Why?
| | Quality of Life | 4 | 2018 | 2892 | 0.090 |
Why?
| | Mental Health | 1 | 2018 | 726 | 0.090 |
Why?
| | Postoperative Care | 1 | 2013 | 261 | 0.090 |
Why?
| | Interleukins | 1 | 2013 | 250 | 0.090 |
Why?
| | Hepatic Insufficiency | 1 | 2010 | 4 | 0.090 |
Why?
| | Cholangiocarcinoma | 1 | 2012 | 104 | 0.090 |
Why?
| | Immunosuppressive Agents | 2 | 2013 | 890 | 0.090 |
Why?
| | HIV Infections | 2 | 2023 | 2836 | 0.090 |
Why?
| | Bile Duct Neoplasms | 1 | 2012 | 124 | 0.090 |
Why?
| | Th1 Cells | 2 | 2008 | 143 | 0.080 |
Why?
| | Chemoradiotherapy | 1 | 2012 | 225 | 0.080 |
Why?
| | Preoperative Care | 1 | 2013 | 362 | 0.080 |
Why?
| | Blood Component Transfusion | 1 | 2011 | 84 | 0.080 |
Why?
| | Death Certificates | 1 | 1990 | 30 | 0.080 |
Why?
| | Autopsy | 1 | 1990 | 95 | 0.080 |
Why?
| | Nucleosides | 1 | 2009 | 27 | 0.080 |
Why?
| | Myocardial Stunning | 1 | 2009 | 5 | 0.080 |
Why?
| | Uremia | 1 | 2009 | 16 | 0.080 |
Why?
| | Primary Health Care | 2 | 1993 | 1738 | 0.080 |
Why?
| | Longitudinal Studies | 4 | 2016 | 2844 | 0.080 |
Why?
| | Prodrugs | 1 | 2009 | 52 | 0.080 |
Why?
| | Aged, 80 and over | 9 | 2015 | 7635 | 0.080 |
Why?
| | Erythrocyte Transfusion | 1 | 2011 | 194 | 0.070 |
Why?
| | Vitamin B 12 Deficiency | 1 | 1988 | 81 | 0.070 |
Why?
| | Drug Discovery | 1 | 2009 | 142 | 0.070 |
Why?
| | MicroRNAs | 1 | 2015 | 692 | 0.070 |
Why?
| | RNA | 1 | 2015 | 921 | 0.070 |
Why?
| | Cross Infection | 1 | 2011 | 256 | 0.070 |
Why?
| | Thrombelastography | 2 | 2022 | 154 | 0.070 |
Why?
| | Urinary Incontinence | 1 | 1988 | 66 | 0.070 |
Why?
| | Interferon-gamma | 2 | 2008 | 789 | 0.070 |
Why?
| | Acute Lung Injury | 1 | 2011 | 287 | 0.070 |
Why?
| | Registries | 1 | 2016 | 2035 | 0.070 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 2031 | 0.070 |
Why?
| | Propionates | 2 | 2005 | 39 | 0.070 |
Why?
| | Risk Factors | 8 | 2020 | 10388 | 0.070 |
Why?
| | Platelet Count | 1 | 2007 | 86 | 0.070 |
Why?
| | Patient Readmission | 2 | 2010 | 697 | 0.070 |
Why?
| | Naphthalenes | 2 | 2005 | 60 | 0.070 |
Why?
| | Ventricular Function, Left | 2 | 2009 | 534 | 0.070 |
Why?
| | Likelihood Functions | 1 | 2007 | 144 | 0.070 |
Why?
| | Interleukin-7 Receptor alpha Subunit | 1 | 2006 | 12 | 0.070 |
Why?
| | Biomarkers | 2 | 2015 | 4149 | 0.070 |
Why?
| | Receptors, Interleukin-7 | 1 | 2006 | 28 | 0.070 |
Why?
| | Anti-Retroviral Agents | 2 | 2023 | 233 | 0.070 |
Why?
| | Viral Load | 2 | 2021 | 466 | 0.060 |
Why?
| | Models, Statistical | 2 | 2015 | 669 | 0.060 |
Why?
| | Behavior Therapy | 1 | 1988 | 264 | 0.060 |
Why?
| | ROC Curve | 1 | 2007 | 554 | 0.060 |
Why?
| | Logistic Models | 3 | 2015 | 2074 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2009 | 435 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2189 | 0.060 |
Why?
| | Heparin | 4 | 2005 | 261 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2020 | 1266 | 0.060 |
Why?
| | Chi-Square Distribution | 2 | 2011 | 530 | 0.060 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 1050 | 0.060 |
Why?
| | Serine Endopeptidases | 1 | 2005 | 123 | 0.050 |
Why?
| | Treatment Failure | 1 | 2005 | 356 | 0.050 |
Why?
| | Skilled Nursing Facilities | 1 | 1985 | 141 | 0.050 |
Why?
| | Ambulatory Care | 1 | 1988 | 546 | 0.050 |
Why?
| | Incidence | 2 | 2010 | 2804 | 0.050 |
Why?
| | Hepatitis B Antibodies | 1 | 2003 | 11 | 0.050 |
Why?
| | Endoscopes, Gastrointestinal | 1 | 2003 | 14 | 0.050 |
Why?
| | Reperfusion Injury | 1 | 2006 | 279 | 0.050 |
Why?
| | House Calls | 1 | 1985 | 138 | 0.050 |
Why?
| | Hepatitis B virus | 1 | 2003 | 40 | 0.050 |
Why?
| | Health Care Surveys | 1 | 2005 | 565 | 0.050 |
Why?
| | Continuity of Patient Care | 1 | 1985 | 284 | 0.050 |
Why?
| | Kidney Failure, Chronic | 1 | 2009 | 570 | 0.050 |
Why?
| | Colectomy | 1 | 2003 | 100 | 0.050 |
Why?
| | Pilot Projects | 3 | 2009 | 1710 | 0.050 |
Why?
| | Risk Assessment | 4 | 2015 | 3457 | 0.050 |
Why?
| | Aging | 1 | 1993 | 1864 | 0.050 |
Why?
| | Choledochostomy | 1 | 2022 | 11 | 0.050 |
Why?
| | Length of Stay | 3 | 2011 | 1215 | 0.050 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2022 | 28 | 0.050 |
Why?
| | Plasma | 2 | 2014 | 212 | 0.050 |
Why?
| | Clinical Protocols | 1 | 2003 | 271 | 0.050 |
Why?
| | Adenoma | 1 | 2024 | 230 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2002 | 303 | 0.050 |
Why?
| | DNA, Viral | 1 | 2003 | 364 | 0.040 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2021 | 20 | 0.040 |
Why?
| | Sustained Virologic Response | 1 | 2021 | 40 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 78 | 0.040 |
Why?
| | Government | 1 | 2000 | 13 | 0.040 |
Why?
| | Health Planning Councils | 1 | 2000 | 7 | 0.040 |
Why?
| | Critical Care | 1 | 1985 | 601 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2006 | 900 | 0.040 |
Why?
| | Blood Coagulation | 1 | 2022 | 255 | 0.040 |
Why?
| | Thrombosis | 1 | 2004 | 371 | 0.040 |
Why?
| | Mental Disorders | 1 | 1988 | 1077 | 0.040 |
Why?
| | Referral and Consultation | 1 | 1985 | 786 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2023 | 539 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2022 | 213 | 0.040 |
Why?
| | Muscular Atrophy | 1 | 2000 | 86 | 0.040 |
Why?
| | Feasibility Studies | 2 | 2004 | 956 | 0.040 |
Why?
| | Baltimore | 1 | 1999 | 60 | 0.040 |
Why?
| | Nephrectomy | 1 | 2020 | 169 | 0.040 |
Why?
| | Specialization | 1 | 2000 | 144 | 0.040 |
Why?
| | Anticoagulants | 1 | 2004 | 664 | 0.040 |
Why?
| | History, 20th Century | 1 | 2000 | 325 | 0.040 |
Why?
| | Hospitals, University | 1 | 1999 | 182 | 0.040 |
Why?
| | Streptokinase | 2 | 1997 | 10 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 786 | 0.040 |
Why?
| | Adolescent | 6 | 2015 | 21513 | 0.040 |
Why?
| | Postoperative Period | 2 | 2016 | 342 | 0.040 |
Why?
| | Islands | 1 | 2018 | 4 | 0.040 |
Why?
| | Indonesia | 1 | 2018 | 24 | 0.040 |
Why?
| | Linear Models | 1 | 2021 | 849 | 0.040 |
Why?
| | Cardiac Surgical Procedures | 1 | 2004 | 530 | 0.040 |
Why?
| | General Surgery | 1 | 2000 | 173 | 0.040 |
Why?
| | Oxazines | 1 | 2018 | 30 | 0.040 |
Why?
| | Withholding Treatment | 1 | 2018 | 76 | 0.040 |
Why?
| | Phylogeography | 1 | 2018 | 54 | 0.040 |
Why?
| | Diagnosis-Related Groups | 1 | 1997 | 31 | 0.030 |
Why?
| | Geography | 1 | 2018 | 200 | 0.030 |
Why?
| | Patient Admission | 1 | 1999 | 197 | 0.030 |
Why?
| | Microsatellite Repeats | 1 | 2018 | 168 | 0.030 |
Why?
| | Safety | 1 | 1999 | 338 | 0.030 |
Why?
| | Osteoporosis | 1 | 2000 | 243 | 0.030 |
Why?
| | Area Under Curve | 1 | 2018 | 314 | 0.030 |
Why?
| | DNA, Mitochondrial | 1 | 2018 | 200 | 0.030 |
Why?
| | Tissue Plasminogen Activator | 2 | 1997 | 224 | 0.030 |
Why?
| | Cause of Death | 2 | 2007 | 434 | 0.030 |
Why?
| | Clinical Competence | 1 | 2024 | 1118 | 0.030 |
Why?
| | Pyridones | 1 | 2018 | 168 | 0.030 |
Why?
| | Data Collection | 1 | 1999 | 673 | 0.030 |
Why?
| | Attitude | 1 | 1998 | 259 | 0.030 |
Why?
| | Myocardial Reperfusion Injury | 1 | 1997 | 135 | 0.030 |
Why?
| | Lymphocytes | 1 | 2018 | 397 | 0.030 |
Why?
| | China | 1 | 2016 | 217 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 329 | 0.030 |
Why?
| | Piperazines | 1 | 2018 | 350 | 0.030 |
Why?
| | Phlebotomy | 1 | 2015 | 21 | 0.030 |
Why?
| | Population | 1 | 2015 | 35 | 0.030 |
Why?
| | 2-Naphthylamine | 1 | 2014 | 7 | 0.030 |
Why?
| | Uracil | 1 | 2014 | 31 | 0.030 |
Why?
| | Half-Life | 1 | 2015 | 164 | 0.030 |
Why?
| | Family Characteristics | 1 | 2016 | 191 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2016 | 499 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2014 | 90 | 0.030 |
Why?
| | Biological Assay | 1 | 2015 | 124 | 0.030 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 72 | 0.030 |
Why?
| | North America | 1 | 2015 | 313 | 0.030 |
Why?
| | Lactams, Macrocyclic | 1 | 2014 | 49 | 0.030 |
Why?
| | Valine | 1 | 2014 | 82 | 0.030 |
Why?
| | Femoral Artery | 1 | 2015 | 179 | 0.030 |
Why?
| | Cadaver | 1 | 2015 | 296 | 0.030 |
Why?
| | Base Sequence | 1 | 2018 | 2181 | 0.030 |
Why?
| | Ritonavir | 1 | 2014 | 74 | 0.030 |
Why?
| | Phylogeny | 1 | 2018 | 904 | 0.030 |
Why?
| | Social Class | 1 | 2016 | 282 | 0.030 |
Why?
| | Hepatocytes | 1 | 2014 | 220 | 0.030 |
Why?
| | Frail Elderly | 1 | 1994 | 131 | 0.030 |
Why?
| | Sex Characteristics | 2 | 2015 | 762 | 0.030 |
Why?
| | DEAD Box Protein 58 | 1 | 2013 | 9 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 402 | 0.030 |
Why?
| | Leukocytes | 1 | 2014 | 311 | 0.020 |
Why?
| | Case-Control Studies | 2 | 2013 | 3556 | 0.020 |
Why?
| | Cholestasis | 1 | 2015 | 235 | 0.020 |
Why?
| | Neutrophils | 1 | 2018 | 1238 | 0.020 |
Why?
| | Pain | 1 | 2018 | 756 | 0.020 |
Why?
| | Mutation | 1 | 2023 | 3958 | 0.020 |
Why?
| | Nitriles | 1 | 2013 | 172 | 0.020 |
Why?
| | Medicare Part B | 1 | 1991 | 3 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 1998 | 806 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 2013 | 216 | 0.020 |
Why?
| | Physical Examination | 1 | 1993 | 241 | 0.020 |
Why?
| | Alcoholism | 1 | 2018 | 807 | 0.020 |
Why?
| | Emotions | 1 | 2016 | 548 | 0.020 |
Why?
| | Lumbar Vertebrae | 1 | 1993 | 246 | 0.020 |
Why?
| | Sulfonamides | 1 | 2014 | 513 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2013 | 433 | 0.020 |
Why?
| | Prevalence | 1 | 2018 | 2734 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 1992 | 273 | 0.020 |
Why?
| | Insurance, Health, Reimbursement | 1 | 1991 | 99 | 0.020 |
Why?
| | Body Weight | 1 | 2015 | 985 | 0.020 |
Why?
| | Anxiety | 1 | 2018 | 1035 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2013 | 564 | 0.020 |
Why?
| | Heart Transplantation | 1 | 1997 | 754 | 0.020 |
Why?
| | Phosphorylation | 1 | 2015 | 1759 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 1998 | 1171 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2005 | 2057 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 532 | 0.020 |
Why?
| | Research Design | 1 | 2016 | 1139 | 0.020 |
Why?
| | Neoadjuvant Therapy | 1 | 2012 | 404 | 0.020 |
Why?
| | Erythrocytes | 1 | 2015 | 700 | 0.020 |
Why?
| | Pyrimidines | 1 | 2013 | 470 | 0.020 |
Why?
| | Anemia, Pernicious | 1 | 1988 | 9 | 0.020 |
Why?
| | Urinary Incontinence, Stress | 1 | 1988 | 15 | 0.020 |
Why?
| | Depression | 1 | 2018 | 1397 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 1993 | 1483 | 0.020 |
Why?
| | Obesity | 1 | 2022 | 2992 | 0.020 |
Why?
| | Fibrinogens, Abnormal | 1 | 2008 | 4 | 0.020 |
Why?
| | Biofeedback, Psychology | 1 | 1988 | 37 | 0.020 |
Why?
| | CD24 Antigen | 1 | 2008 | 20 | 0.020 |
Why?
| | Vitamin B 12 | 1 | 1988 | 128 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2015 | 1774 | 0.020 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 81 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2010 | 512 | 0.020 |
Why?
| | Myocardial Contraction | 1 | 2009 | 341 | 0.020 |
Why?
| | Genes, MHC Class II | 1 | 2007 | 74 | 0.020 |
Why?
| | Societies, Medical | 1 | 1991 | 820 | 0.020 |
Why?
| | Cytomegalovirus | 1 | 2007 | 157 | 0.020 |
Why?
| | Child | 2 | 2021 | 21935 | 0.020 |
Why?
| | Hospital Mortality | 1 | 2011 | 911 | 0.020 |
Why?
| | Nurse Practitioners | 1 | 1988 | 138 | 0.020 |
Why?
| | Hospitalization | 1 | 1996 | 2199 | 0.020 |
Why?
| | Organizational Affiliation | 1 | 1985 | 8 | 0.020 |
Why?
| | Immunity, Cellular | 1 | 2008 | 268 | 0.020 |
Why?
| | Stroke Volume | 1 | 2009 | 612 | 0.020 |
Why?
| | Internal Medicine | 1 | 1988 | 265 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 1985 | 206 | 0.010 |
Why?
| | Pressure Ulcer | 1 | 1985 | 46 | 0.010 |
Why?
| | Waiting Lists | 1 | 2007 | 266 | 0.010 |
Why?
| | Partial Thromboplastin Time | 1 | 2005 | 57 | 0.010 |
Why?
| | Ultrasonography | 1 | 2009 | 759 | 0.010 |
Why?
| | Dementia | 1 | 1988 | 259 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 5472 | 0.010 |
Why?
| | Fluid Therapy | 1 | 1985 | 147 | 0.010 |
Why?
| | Epitopes | 1 | 2006 | 479 | 0.010 |
Why?
| | Immunologic Memory | 1 | 2006 | 353 | 0.010 |
Why?
| | Alleles | 1 | 2007 | 891 | 0.010 |
Why?
| | International Normalized Ratio | 1 | 2004 | 47 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2426 | 0.010 |
Why?
| | Pneumonia | 1 | 1990 | 639 | 0.010 |
Why?
| | Blood Coagulation Tests | 1 | 2004 | 67 | 0.010 |
Why?
| | Intraoperative Care | 1 | 2004 | 52 | 0.010 |
Why?
| | Canada | 2 | 1997 | 418 | 0.010 |
Why?
| | Physician's Role | 1 | 1985 | 211 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2006 | 1178 | 0.010 |
Why?
| | Drug Monitoring | 1 | 2004 | 218 | 0.010 |
Why?
| | Blood Pressure | 1 | 2009 | 1786 | 0.010 |
Why?
| | Ischemia | 1 | 2005 | 409 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2014 | 5778 | 0.010 |
Why?
| | Electrocardiography | 1 | 2005 | 629 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2007 | 1477 | 0.010 |
Why?
| | Colorado | 1 | 2011 | 4565 | 0.010 |
Why?
| | Foundations | 1 | 2000 | 28 | 0.010 |
Why?
| | Hemorrhage | 1 | 2005 | 722 | 0.010 |
Why?
| | Organizational Objectives | 1 | 2000 | 73 | 0.010 |
Why?
| | Models, Biological | 1 | 2007 | 1783 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 1985 | 766 | 0.010 |
Why?
| | Phenotype | 1 | 2006 | 3196 | 0.010 |
Why?
| | Education, Medical | 1 | 2000 | 266 | 0.010 |
Why?
| | Vascular Patency | 1 | 1997 | 106 | 0.010 |
Why?
| | Coronary Circulation | 1 | 1997 | 143 | 0.010 |
Why?
| | Animals | 1 | 2018 | 36940 | 0.010 |
Why?
| | Regression Analysis | 1 | 1997 | 1024 | 0.010 |
Why?
| | Child, Preschool | 1 | 2009 | 11074 | 0.010 |
Why?
| | Interviews as Topic | 1 | 1997 | 786 | 0.010 |
Why?
| | Institutionalization | 1 | 1992 | 13 | 0.010 |
Why?
| | Survival Rate | 1 | 1997 | 1972 | 0.010 |
Why?
| | Organizational Policy | 1 | 1991 | 84 | 0.010 |
Why?
| | Sex Factors | 1 | 1997 | 2071 | 0.010 |
Why?
|
|
Burton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|